Aesica’s high capacity manufacturing facility at its Queenborough, UK site has been successfully validated for commercial production. The company invested $45 million to expand commercial production for a solid dose medication used to treat Type 2 diabetes. The product is sold globally and is ready for worldwide export.
The expanded facility is capable of producing more than 1 billion tablets per year and was designed to accommodate potential future expansion to produce more than 2.5 billion tablets a year. The new facility contains highly technical and specialist equipment including spray granulators, coaters, tablet presses, powder handling systems and large capacity blenders. The company added 10,000 square meters to the existing Queenborough site and has a dedicated workforce of 55 technicians, with future expansion plans to increase the staffing level to more than 100.
Dr. Robert Hardy, chief executive officer of Aesica Pharmaceuticals, said, “The validation of this facility for commercial production is a major milestone for the company and brings to fruition what has been a significant investment. Aesica is already a major exporter of finished dose products and the investment in this facility reflects the continued growth in export demand. This state-of-the-art facility will allow us to manufacture a high quality product used to treat one of the world’s most prevalent diseases and has the capability to double its capacity in the future, representing an expanding revenue stream for Aesica.”